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Abstract
Background: HIV-1 is a pathogen that T cell responses fail to control. HIV-1gp120 is the surface viral envelope glycoprotein
that interacts with CD4 T cells and mediates entry. HIV-1gp120 has been implicated in immune dysregulatory functions that
may limit anti-HIV antigen-specific T cell responses. We hypothesized that in the context of early SHIV infection, immune
dysregulation of antigen-specific T-effector cell and regulatory functions would be detectable and that these would be
associated or correlated with measurable concentrations of HIV-1gp120 in lymphoid tissues.
Methods: Rhesus macaques were intravaginally inoculated with a Clade C CCR5-tropic simian-human immunodeficiency
virus, SHIV-1157ipd3N4. HIV-1gp120 levels, antigen-specificity, levels of apoptosis/anergy and frequency and function of
Tregs were examined in lymph node and blood derived T cells at 5 and 12 weeks post inoculation.
Results/Conclusions: We observed reduced responses to Gag in CD4 and gp120 in CD8 lymph node-derived T cells
compared to the peripheral blood at 5 weeks post-inoculation. Reduced antigen-specific responses were associated with
higher levels of PD-1 on lymph node-derived CD4 T cells as compared to peripheral blood and uninfected lymph node-
derived CD4 T cells. Lymph nodes contained increased numbers of Tregs as compared to peripheral blood, which positively
correlated with gp120 levels; T regulatory cell depletion restored CD8 T cell responses to Gag but not to gp120. HIV gp120
was also able to induce T regulatory cell chemotaxis in a dose-dependent, CCR5-mediated manner. These studies contribute
to our broader understanding of the ways in which HIV-1 dysregulates T cell function and localization during early infection.
Citation: Santosuosso M, Righi E, Hill ED, Leblanc PR, Kodish B, et al. (2011) R5-SHIV Induces Multiple Defects in T Cell Function during Early Infection of Rhesus
Macaques Including Accumulation of T Reg Cells in Lymph Nodes. PLoS ONE 6(4): e18465. doi:10.1371/journal.pone.0018465
Editor: Derya Unutmaz, New York University, United States of America
Received September 13, 2010; Accepted March 9, 2011; Published April 5, 2011
Copyright:  2011 Santosuosso et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was completed via support of MCP (National Institutes of Health (NIH) RO1 AI49757), RMR (NIH grants PO1 AI048240 and RO1 DE016013) and
Yerkes National Primate Research center (Grant #RR00165). MS is a research fellow of the Canadian Institute of Health. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mpoznansky@partners.org
Introduction
It is increasingly clear that a single HIV virion or a small founder
virus population infects a target cell in the mucosa and initiates a
localized infection that is followed by systemic spread of the virus
[1,2,3,4]. Early HIV infection is characterized by a reduction of CD4
Tcellsapproximately9dayspostonsetofacuteillness,followedbyan
increased number of CD8 T cells and an inversion of the CD4/CD8
T cell ratio [5,6,7]. These kinetics are associated with an increasing
plasma viralload and rising numbersofHIV-specific CD8 T cells. By
3–6monthspost-inoculation,theplasmaviralloadhasequilibratedto
a set point that is highly correlated with disease progression [5,8,9].
These early events set the stage for a prolonged and multi-
dimensional negative impact on the host immune system that
characteristically fails to eradicate the infection [8,9,10,11].
HIV proteins, including the surface envelope glycoprotein
gp120, perform critical functions during the viral life cycle as well
as playing a direct role in the immune pathogenesis of HIV/AIDS.
For example, it has been shown that HIV-1 gp120 can mediate
both viral entry and dysregulate immune cell function through its
well-described interaction with cellular receptors, including CD4
and the chemokine co-receptors, CXCR4 and CCR5 (for X4 and
R5 tropic viruses, respectively). HIV gp120 has been extensively
studied in vitro with respect to its effects on a variety of both stromal
and immune cell types [10,11,12]. HIV gp120 can impair
dendritic cell maturation or induce dendritic cells to become
immunosuppressive [12,13,14]. HIV gp120 has been shown in vitro
to dysregulate T cell functions, including TCR desensitization,
interference with co-stimulation, induction of apoptosis, and T cell
migration [15,16,17,18,19,20,21]. The impairment of these
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18465functions may have a dramatic effect on the formation and
stability of effective anti-HIV immunity beyond the characteristic
depletion of CD4 T cells seen in HIV/AIDS.
In vivo, gp120-induced immune dysfunction is more difficult to
quantify, although human studies have consistently shown that
gp120 is poorly targeted by both humoral and cellular immune
responses [22,23,24,25]. In addition, there is a growing body of
evidence to support the view that levels of gp120 required for
immune dysregulation in vitro are present in lymphoid tissues in vivo
[26]. Accumulation of high levels of gp120 in lymphoid organs of
early SHIV-infected rhesus monkeys (RM) have been demonstrated
[27], and high levels of the envelope protein have been found in the
lymphoid tissues of HIV-1-infected humans with very low or
undetectable viral loads [28,29]. These data support the view that
the earliest events after primary infection, including exposure of
immune cells to high local or systemic levels of gp120, play a major
role in the long-term outcome of infection [1,3,30]. Taken together,
these studies support the view that HIV-1 gp120 may play a role in
immune dysfunction in lymphoid tissues as infection progresses.
We examined the hypothesis that a biologically relevant R5
HIV-1 gp120, in the context of early mucosal SHIV challenge,
results in multimodal dysregulation of T cell-mediated immune
function that in some cases, are associated with persistently high
levels of gp120 in lymphoid tissues. Mucosal R5-SHIV inoculation
of RM was chosen as a model system because 90 percent of all
HIV infections among humans involve mucosal exposure to an
R5-tropic virus. In this non-human primate study, we demonstrate
early immune dysregulation of CD8 gp120-specific and CD4 Gag-
specific T cells in the lymph nodes (LN), as compared to the
peripheral blood. We found no enhancement of antigen-induced
cell death in LN derived T cells compared to the T cells from the
peripheral blood (PB); however, we observed increased levels of
PD-1 expression on CD4 T cells in the LN as compared to PB and
naı ¨ve LN samples. Furthermore, LN gp120 levels correlated with
an increased proportion of regulatory T cells (Treg) in lymphoid
tissues. Depletion of CD4
+CD25
+ Treg cells augmented Gag-
specific CD8 T cell responses, whereas gp120-specific T cells
remained impaired in this context. Finally, we demonstrated that
R5 gp120 could induce Treg chemotaxis in vitro in a CCR5
mediated and concentration dependent manner. This study
demonstrates multiple T cell-mediated immune defects that are
associated with HIV-1 gp120 in LN during the first 12 weeks of
R5 clade C SHIV infection.
Materials and Methods
Ethics Statement
The studies were conducted in accordance with National
Institute of Health guidelines on the care and use of laboratory
animals at the Yerkes National Primate Research Center
((YNPRC), Emory University, Atlanta, GA), which is fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. The Animal Care and Use
CommitteeofYNPRCandDFCIapproved allanimalexperiments.
Animals
Six rhesus macaques (RM) of Indian origin were exposed
intravaginally to various dilutions of a SHIV-1157ipd3N4 (R5-
SHIV) stock grown in RM peripheral blood mononuclear cells
(PBMC) (227 ng/ml of p24; 4610
6 /ml) 50% tissue culture
infectious doses (TCID50) as titrated in TZM-bl cells. This virus is
exclusively R5-tropic [31,32]. Two animals that received the lowest
mucosal dose (1:50) of SHIV did not seroconvert and were
challenged secondarily with 1 ml of viral stock via the intravenous
route (Table 1). Peripheral blood (PB) and peripheral nodes,
including axillary LN were sampled at 5 weeks and 12 weeks post-
inoculation. Some LN were frozen and stored at -80uC for later
quantitationofgp120.Mononuclearcells(MNC)wereisolatedfrom
PB via Ficoll gradient enrichment as previously described [27].
MNC were obtained from the LN via physical disruption with cell
lifters in a Petri dish and enriched by Ficoll gradient centrifugation.
Samples were frozen at 280uC prior to use in vitro assays.
Quantitation of HIV gp120 and SIV p27 in tissue
LN biopsy specimens from infected and non-infected animals
were thawed, weighed and suspended in 3.5 ml of lysis buffer
(RIPA containing protease inhibitors), per gram. After being
subjected to two freeze/thaw cycles, samples were spun at
16,0006 g for 10 min and supernatants were frozen at 280uC
prior to analysis as previously described [29]. Thawed samples
were diluted in RPMI1640 containing 10% fetal bovine serum
(FBS) and aliquots were assayed using the HIV-1 gp120 Antigen
Capture Assay (Advanced BioScience Laboratories, Inc., Ken-
sington, MD) and a signal amplification kit ELAST ELISA
Amplification (Perkin Elmer, San Jose, CA). Briefly, the modifi-
cations to the assay consisted of diluting the HIV-1 gp120 Antigen
Capture Assay kit conjugate 1:1 with 1% BSA PBS-Tween 20
(0.05%) followed by 60 min incubation at 37uC. Next, 100 mlo f
Biotinyl Tyramide Solution (ELAST ELISA Amplification) was
added to each well, followed by a 20 min incubation at room
temperature. Detection consisted of adding 100 ml of diluted
Streptavidin–HRP Concentrate from the ELAST ELISA Ampli-
fication kit; 1000 fold with 1% BSA PBS-Tween 20 (0.05%) to
each well and incubating the plate at room temperature for
30 min. The peroxidase substrate and the stop solution from the
HIV-1 gp120 Antigen Capture Assay kit were used as described by
the manufacturer. After stopping the reaction, absorption was
measured at 450 nm as previously described [29]. SIV p27 was
measured via a Retrotek SIV p27 antigen ELISA as per
manufacturer’s instructions (Zeptometrix, Buffalo, NY.). Antigen
concentrations were calculated as the number picograms per ml of
tissue, according to the following equation: concentration of
antigen = {[(tissue volume + media added)/tissue volume] 6
antigen amount}/tissue volume.
Flow cytometry and intracellular cytokine staining (ICS)
PB and LN derived MNC were stimulated for 5 hours in the
presence of an inhibitor of Golgi function (Golgi plug, BD
Table 1. Levels of gp120 and p27 in the Plasma, Lymph Node
and Spleen of RM 12 weeks post-inoculation with R5-SHIV.
Animal Tissue gp120 (pg/ml) p27 (pg/ml)
Rbo-6 Plasma 0.00 21.53
LN 71.81 1832.04
Spleen 297.63 545.57
RBw-8 Plasma 0.00 62.82
LN 170.37 447.72
Spleen 278.16 603.89
Ryb-6 Plasma 0.00 7.54
LN 176.96 687.00
Spleen 451.38 1064.68
LN: Lymph Node.
doi:10.1371/journal.pone.0018465.t001
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CD28.2 and 9F10, BD Biosciences). Antigen-specific stimulation
utilized 2 mg/ml of overlapping peptide pools from either a
consensus gp120 of HIV clade C (kindly provided by Dr. Christian
Brander), or from SIVmac239 Gag (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH,
15mers). Multi-parameter surface staining for CD3, CD4, CD8,
CD25, CD127, (CD3 clone Sp34-2, CD4 clone L200, CD8 clone
SK1, CD25 clone M-A251, CD127 clone hIL-7R-M21 BD
Biosciences) and PD-1 (clone EH12.2H7, Biolegend, San Diego,
CA) were carried out, followed by permeabilization and
intracellular staining for IFN-c or FoxP3 as per manufacturer’s
instructions (IFN-c clone B27 BD Biosciences, FoxP3 clone
PHC101 eBiosciences). Analysis was completed using FlowJo
Software (TreeStar, Ashland, OR) and gating was completed using
a ‘fluorescence minus one’ (FMO) approach.
Activation- Induced Cell Death (AICD)
A 96 well round-bottom plate was coated with 1 mg of anti-CD3
monoclonal antibody (clone Sp34-2, BD Biosciences) overnight at
4uC. Previously frozen samples from PB and LN were cultured in
the presence or absence of plate-bound anti-CD3 with the addition
of anti-CD28, anti-CD49d for 5 hours at 37uC and 5% CO2.
CD25 Depletion and CD4+CD25+ Isolation
PB and LN derived MNC were depleted via a MACS CD25
depletion kit (Miltenyi Biotec, Auburn, CA) as per the manufac-
turer’s instructions. CD25 depletion was confirmed via flow
cytometry and was 7868%. Depleted or non-depleted cells were
then stimulated and stained as described above to examine the role
of CD25 cells on T-effector cell functions. For migration studies,
human PBMC were obtained via a Ficoll spin and CD4+CD25+
T regulatory cells were isolated via a Human CD4+CD25+
MACS isolation kit (Miltenyi Biotec, Auburn, CA), as previously
described [27]. Cell subpopulation purity was confirmed via flow
cytometry to be greater than 80%.
Transmigration Assay
T cell migration was measured using Transwells (96-well format,
3-mm pore; ChemoTx System, Neuro Probe Inch, Gaithersburg,
MA) as previously described [33]. Briefly, 7,000 CD4+CD25+ T-
regs were loaded into the upper chamber, and 30 ml of medium
alone or media supplemented with CCR5 tropic YU2 gp120
(ImmunoDiagnositcs, Woburn, MA) was added to the lower or
upper chamber at the concentrations of 500 pg/ml, 5 ng/ml, and
500 ng/ml [34]. After a three hour incubation at 37uC and 5%
CO2, cells in the upper chamber of the transwell were removed and
migrated cells in the lower chamber were counted. using a
hemocytometer. The normalized transmigration index was calcu-
lated as the ratio between the cells counted in the presence of R5
gp120 and when cells were exposed to media alone in upper and
lower chambers. To determine whether T-cell migration was G
protein-mediated, the cells were pre-incubated with 100 ng/ml
pertussis toxin (PTx; Sigma Aldrich) for 1 h at 37uC, washed, and
then loaded in the chemotaxis chamber. In order to determine
whether the migration of cells in response to R5 gp120 gradients
was CCR5 dependent, cells were pre-incubated with the CCR5
antagonist, TAK-779, at a concentration of 40 nM [34].
Statistical analysis
All statistical analyses were performed in collaboration with Dr.
Gebremichael at the Department of Biostatistics and Computa-
tional Biology at the Harvard School of Public Health. The
analyses were completed using the Student t-Test and determina-
tions of correlation coefficients using Excel software.
Results
Quantifiable amounts of gp120 in secondary lymphoid
organs of RM at 12 weeks post mucosal R5-SHIV
inoculation
We have previously demonstrated that gp120 is found in the
secondary lymphoid organs of individuals with chronic HIV
infection at levels that were disproportionally high in comparison
to both local p24 concentrations or plasma viral loads[29]. We
sought to examine if during early mucosal R5-SHIV challenge, R5
gp120 would also be found at high levels in LN and spleen. At 12
weeks post-inoculation, we observed measureable amounts of
gp120 in LN as compared to PB (Table 1, 139.7634 pg/ml).
Interestingly, at 12 weeks, we also observed significantly more
gp120 in the spleen of infected RM than in the LN
(342.4654.7 pg/ml, vs 12 week LN; p,0.05 non-paired T-test),
in spite of the fact that half of the animals (3/6) had non-detectable
viral loads in their PB (,1,300 copies/ml)[35]. Furthermore, we
observed considerably lower levels of p27 than the expected
Gag:gp120 ratio would lead one to predict. Previous studies of the
protein content of HIV virions have demonstrated a ratio of p24 to
gp120 to vary between 6:1 and 60:1 (table 1, 12 weeks p,0.05
spleen, p,0.001 LN vs an expected 6:1 Gag:gp120 ratio,
p,0.0001 60:1 Gag:gp120 ratio) [29,36]. These data demonstrate
that early after inoculation there is a gradient of gp120 between
high detectable levels in LN, as described above, and undetectable
amounts in PB at 12 weeks.
Reduced Gag-specific CD4 and gp120 specific CD8 T cell
responses in the LN of RM during early infection
We examined responses of T cells derived from PB and LN
upon stimulation with overlapping peptide pools of gp120 and
Gag antigens at both 5 and 12 weeks post-inoculation. All animals
were productively infected and had measurable viral loads at 5
weeks post inoculation. Half (3/6) of the RM subsequently had
viral loads that were below the level of detection at 12 weeks post
inoculation (Figure 1A). HIV-1gp120 specific IFN-c+ CD4 T cells
were lower in LN compared to PB, although this was not
significant (Figure 1B &1C). However, the frequency of gp120-
specific IFN-c
+ CD8 T cells was lower in LN than in PB at both 5
and 12 weeks post-inoculation (CD8 p,0.05, Figure 1D & 1E).
Furthermore, in general gp120-specific CD4 and CD8 IFN-c+ T
cell responses in LN did not increase over time post R5-SHIV
inoculation, whereas anti-gp120 CD4 and CD8 IFN-c+ T cell
responses in the PB increased over time between 5 and 12 weeks
post-inoculation(Figure 1C & E). We also observed a different
temporal pattern of Gag-specific responses. We observed a
significant reduction with respect to Gag-specific CD4 T cells in
LN as compared to PB at 5 weeks but not at 12 weeks post R5-
SHIV inoculation (5 weeks: p,0.01, Figure 1F). Gag-specific CD4
and CD8 T cells increased over time regardless of anatomic
location (Figure 1F & G). These data suggest that fewer gp120-
specific T cells reside or are maintained in LN than in PB and that
this effect is stable over time.
Increased levels of Activation-Induced Cell Death (AICD)
occur during early infection but are not associated with
HIV-1 gp120 in lymph nodes
Previous in vitro studies have demonstrated that gp120 can
enhance T cell sensitivity to AICD and therefore we hypothesized
R5-SHIV Causes Multiple Defects in T Cell Function
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enhanced activation of LN-derived T cells [16,20,21,37]. We
examined the ability of T cells to undergo AICD after polyclonal
stimulation and compared the results between T cells derived from
either PB or LN from naı ¨ve RM or RM during early infection at 5
and 12 weeks post-inoculation. Upon examination of CD4 and
CD8 T cells derived from naive animals, we found that PB-derived
T cells demonstrated induction of AICD and stimulation-
increased apoptosis, as expected (p,0.005 PBMC, Figure 2A &
B). Interestingly, the basal levels of CD4 T cell apoptosis at 5 and
12 weeks (non-stimulated) were higher in infected RM as
compared to PB derived T cells from naı ¨ve animals (p,0.005
PBMC 5 weeks, p,0.05 PBMC 12 weeks, Figure 2A). In contrast
to naı ¨ve animals, PB-derived CD4 T cells from R5-SHIV-infected
animals could not be further stimulated via anti-CD3 at either
time point (Figure 2A). A similar pattern was observed with respect
to CD8 T cells: PB-derived cells had higher basal apoptosis at 5
weeks post-inoculation compared to PB-derived T cells from naı ¨ve
animals (p,0.05 PBMC naı ¨ve vs 5 weeks, Figure 2B). Moreover,
LN-derived CD8 T cells did not demonstrate enhanced levels of
apoptosis upon stimulation with CD3 at either 5 or 12 weeks post-
inoculation (Figure 2B). Increased levels of AICD in LN were not
correlated with HIV gp120 levels in these tissues (data not shown).
These results suggest that AICD may not play a major role in
Figure 1. Reduced antigen-specific CD4 and CD8 T cell responses in LN RM during early R5-SHIV infection. RM were inoculated
intravaginally (n=4) or intravenously (n=2) with SHIV-1157ipd3N4 (R5-SHIV). Blood samples were drawn for viral load analysis at 0, 1, 2, 3, 8 and 12
weeks post infection (A). Paired peripheral blood samples (PB) and lymph nodes (LN) from RM during early infection were sampled at 5 and 12 weeks
post-inoculation (B-G). PB and LN lymphocytes were stimulated with overlapping clade C gp120 peptide pools at 5 and 12 weeks post inoculation
and IFN-c
+ gp120-specific CD4 (B,C) and CD8 (D,E) T cell were assayed. F & G) PB and LN derived cells were stimulated with overlapping SIVmac239
Gag peptide pools at 5 and 12 weeks post inoculation and IFN-c
+ Gag-specific CD4 (F) and CD8 (G) T cell responses were assayed. Data representative
of frequency of total (C,E-G) or frequency of parent (B,D) are shown. Error bars 6SEM, *p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0018465.g001
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infection.
Enhanced expression of PD-1 in LN derived T cells from
RM during early infection
Although, we observed no differences in apoptosis that were
associated with reduced antigen-specific LN responses we
proposed that T cell anergy may in part account for the observed
immune dysregulation. Previous studies have demonstrated that
during chronic HIV infection, levels of PD-1 are upregulated and
correlated with anergic T cell responses to HIV antigens
[38,39,40]. Furthermore, the blockade of PD-1 restores T cell
function in animal models [41,42]. To further elucidate immune
dysregulation in LN during early infection, we examined the level
of PD-1 on T cells derived from PB and LN of naı ¨ve and infected
RM at 5 and 12 weeks post-R5-SHIV inoculation. We observed
no major differences with respect to the proportion of T cells
expressing PD-1 in any of the groups (data not shown). However,
when we examined the amount of receptor on a per-cell basis, we
observed higher levels of PD-1 on LN-derived CD4 T cells from
R5-SHIV-infected RM at 5 weeks compared to cells from naı ¨ve
RM as measured by mean fluorescence intensity (MFI, p,0.005
Figure 3A). Whereas, PB-derived CD4 T cells at 5 weeks post-
inoculation had levels of PD-1 similar to those seen in naı ¨ve
animals (Figure 3A). In general, we also observed more PD-1 on
CD4 T cells derived from LN at both 5 and 12 weeks post-
inoculation as compared to PB-derived CD4 T cells (5 weeks
p.0.005,12 weeks p,0.05 Figure 3A). We also observed a similar
Figure 2. Enhanced basal T cell apoptosis from PB, but not LN of R5-SHIV-infected RM. Naı ¨ve and R5-SHIV challenged RM were sampled at
5 and 12 weeks post-inoculation. PB and LN samples from either naı ¨ve or 5 and 12 weeks post-inoculation samples were either non-stimulated (NS) or
stimulated with plate-bound anti-CD3 (CD3) for 24 hours. A) Percent of apoptotic CD4 T cells from naı ¨ve RM or infected RM at 5 or 12 weeks post
inoculation comparing non-stimulated to CD3 stimulated is shown (naı ¨ve PBMC non-stimulated vs naı ¨ve PBMC stimulated p,0.005; naı ¨ve PBMC non-
stimulated vs 5 weeks infected PBMC non-stimulated p,0.005; naı ¨ve PBMC non-stimulated vs 12 weeks infected non-stimulated p,0.05). B) Percent
of apoptotic T cells from naı ¨ve RM or infected RM at 5 or 12 weeks post inoculation comparing non-stimulated to CD3 stimulated, (naı ¨ve PBMC non-
stimulated vs naı ¨ve PBMC stimulated p,0.005; naı ¨ve PBMC, non-stimulated vs 5 weeks infected PBMC, non-stimulated p,0.05).
doi:10.1371/journal.pone.0018465.g002
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receptor expression was upregulated at 5 weeks post-inoculation
compared to cells from naı ¨ve RM (p,0.005, Figure 3B). These
data suggest that upregulation of PD-1 can be observed in LN-
derived CD4 T cells of R5-SHIV challenged RM during early
infection in LN and not in PB.
Increased frequency of CD4
+CD25
+CD127
low T cells in LN
of RM during early infection correlate with tissue levels of
gp120
We hypothesized that lower frequencies of gp120-specific CD4
and CD8 T cells and to some extent Gag-specific CD4 and CD8 T
cells seen in LN compared to PB, resulted from antigen-specific
Treg suppression. To address this, we examined the proportion of
CD4
+CD25
+CD127
low Treg in PB and LN of SHIV challenged
RM during early infection. We observed CD4
+CD25
+CD127
low T
cells in both PB and LN of RM during early infection
(Figure 4A & B). We found consistently higher frequencies of
CD4
+CD25
+CD127
low T cells at 5 weeks post-inoculation in LN
compared to PB (.85% of all CD4
+CD25
+CD127
low T cells were
FoxP3
+) (5 weeks: p,0.01, Figure 4C, E). In order to determine
whether the observation of increased frequencies of
CD4
+CD25
+CD127
low T cells was associated with decreased
frequencies of IFN-c
+ T cells in LN, we examined the effect of
Tregs on antigen-specific T cell production of IFN-c.T o
accomplish this, we depleted 5 week post-inoculation PB and
LN mononuclear cell samples of CD4
+CD25
+ cells, where we
observed significant differences in the frequencies of Treg and the
greatest difference between IFN-c producing, antigen-specific T
cells (gp120 and Gag) from PB and LN. CD4
+CD25
+ depletion
reduced the level of this subpopulation by 7868%. We observed a
trend toward more Gag-stimulated CD8 T cells producing IFN-c
in the CD4
+CD25
+-depleted samples than in the non-depleted
samples, as shown by the difference between depleted compared to
non-depleted cells (p=0.06, Figure 4F). Interestingly, gp120-
stimulated CD8 T cells were not impacted by the depletion of
CD4
+CD25
+ T cells (data not shown), which is similar to
observations in mouse models where the effects of Tregs are most
potent on immunodominant epitopes [43,44,45]. Although Treg
depletion had no impact on the restoration of CD4 T cell
responses, these results may be difficult to interpret due to the fact
that the Treg depletion step may have reduced the proportion of
Figure 3. Enhanced expression of PD-1 on LN-derived CD4 and CD8 T cells. Naı ¨ve and intravaginally challenged RM were sampled at 5 and
12 weeks post-inoculation. Samples from PB and LN derived lymphocytes were examined by flow cytometry for the amount of PD-1 that was
expressed at 5 and 12 weeks post-inoculation. Mean Fluorescent Intensity (MFI) for CD4 (A) and CD8 (B) of samples from infected and naı ¨ve RM are
shown. Significant increases in PD-1 expression by LN derived CD4 and CD8 T cells were seen at 5 weeks post inoculation compared to naı ¨ve animals.
doi:10.1371/journal.pone.0018465.g003
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levels of CD4
+CD25
+CD127
low T cells in LN of RM at 5 weeks
and 12 weeks post-inoculation positively correlated with the
measured concentration of gp120 in lymphoid tissues (Figure 4G,
r
2=0.7 p=0.035).
Tregs migrate towards R5 gp120 in a CCR5 and G-protein
coupled receptor manner
In view of the finding that LN levels of gp120 correlated with
the number of Tregs in this tissue, we hypothesized that gp120
may play a direct role in Treg recruitment. To examine this, we
investigated the migration of Tregs from human HIV naı ¨ve
donors in response to recombinant R5 HIV-1 gp120. We observed
that Tregs migrated with increasing frequency to an R5 (YU2)
gp120 in a dose-dependent manner (Figure 5A). Furthermore, the
specific CCR5 antagonist, TAK-779, inhibited Treg migration
demonstrating the dependence of this directional migration on
CCR5. Additionally, pertussis toxin, an inhibitor of G-protein
coupled receptor signaling, potently inhibited Treg migration
toward R5 gp120 (Figure 5A). Finally, we observed that Tregs do
not migrate away from R5 gp120 at any concentration of envelope
protein that we examined (Figure 5B). These results suggest that
recruitment of Tregs to lymphoid tissues during HIV infection
may be in part due to the chemoattractant activity of R5 gp120 for
this T cell subpopulation.
Discussion
In this study, we demonstrate a significant impact of early R5-
SHIV infection on critical aspects of T cell function at and beyond
the 5-week time point of maximal CD4 T cell depletion and viral
load, including upregulation of PD-1 expression, differential
suppression of gp120-specific T cell responses and preferential
accumulation of Treg cells in lymphoid tissues. These immune
dysregulatory effects are associated with high levels of the envelope
protein (gp120) of HIV in lymphoid tissues when viral load is low
or undetectable in PB (12 weeks). These data are consistent with a
growing literature describing the effects of gp120 on T and B-cell
function in vitro [10,11,12,13,14,15,16,17,19,23] and gp120-
mediated dysregulation of immune cell function and localization
in vivo [22,27,29,46,47].
Our results reveal consistent differences between the measure-
ments of immune activation and regulation of PB versus LN-
derived CD4 and CD8 T cells, regardless of route of infection
(intravenous or mucosal). These differences are also evident
despite the small sample size and the inclusion of two animals in
this study that were challenged via a non-mucosal route and are
consistent with a similar study performed in the dual-tropic SHIV-
KB9 model using intravenous transmission [27]. In addition, these
data imply that the anti-HIV immune response during early
infection could easily be overestimated if the responses generated
by circulating T cells was the only measurement made in this
Figure 4. Increased numbers of CD4+CD25+CD127low T cells in the LN of R5-SHIV infected RM. RM were sampled at 5 and 12 weeks
post-inoculation. PB and LN samples were examined by multi-colour flow cytometry for the proportion of Treg cells present. A) Representative
dotplots from PB and LN gated on size and granularity as well as CD3 and CD4, and subsequently on CD25 vs CD127 as shown (% frequency of
parent). B) Gating strategy demonstrating the fluorescent minus one scheme utilized as above and CD25 vs CD127 as shown. C & D) Individual RM
Treg cell frequencies of parental gate at 5 weeks post-infection *p,0.05 LN compared to PB (C), and 12 weeks (non-significant) (D) post-infection. E)
Time course of Treg accumulation at 5 and 12 weeks post infection in PB and LN, mean 6SEM. F) LN samples depleted of CD4+CD25+ T cells and
stimulated with overlapping SIVmac239 Gag peptide pools. Data depicted as relative change of Gag- and gp120 specific CD8 responses in
CD4+CD25+ depleted compared to non-depleted samples, (p=0.06 vs change in gp120 specific CD8 T cells.) G) Correlation of Tregs with gp120 in
the LN of intravaginally challenged RM (r
2=0.7, two-tailed p=0.035).
doi:10.1371/journal.pone.0018465.g004
Figure 5. T regulatory cells migrate toward R5 HIV gp120. CD4+CD25+T regulatory cells were purified from naive human PBMC and exposed
to various concentrations of gp120 in a Boyden chamber migration assay. A) Normalized transmigration index of Tregs that migrate towards various
gp120 concentrations (500 pg/ml, 5 ng/ml, 500 ng/ml) in presence of CCR5 antagonist, TAK-779, or pretreated with pertussis toxin (Ptx 100 ng/ml)
(*p,0.05 vs TAK-779). B) Normalized transmigration index of Tregs that migrate away from gp120 concentrations (500 pg/ml, 5 ng/ml, 500 ng/ml) in
presence of CCR5 antagonist, TAK-779 (40 nM), or pretreated with pertussis toxin (Ptx, 100 ng/ml).
doi:10.1371/journal.pone.0018465.g005
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marker of immune activation in lymphoid tissues in HIV has been
the gold standard in both basic science and clinical trials.
Interestingly, there is an increasingly consistent lack of correlation
between PB T cell responses and immune protection in RM
models [24,27,48,49]. Although immune cells residing in LN are
more difficult to sample, they may provide a deeper understanding
of the mechanisms used by the virus to subvert and evade host
immune responses.
The presence of gp120 in LN of RM during early infection was
shown to be associated with dysregulated IFN-c responses of CD4
and CD8 T cells [27]. Previously, our laboratory demonstrated that
the addition of exogenous gp120 to PB CD4 and CD8 T cells
reduced HIV-specific IFN-c responses to those levels observed in
LN [27]. In the current study, increased levels of gp120 and the
impaired IFN-c response observed in LN were associated with
increased levels of the T cell exhaustion marker, PD-1. Moreover,
we observed enhanced basal apoptosis in PB of infected RM,
suggesting that apoptosis may play a role in immune dysregulation,
but this did not correlate with LN gp120 levels, PD-1 levels or
impaired IFN-c responses. The lack of correlation to apoptosis may
be dueto the fact that tissues have differential apoptotic rates during
earlyinfection[50].AlthoughHIVgp120hasbeendemonstratedto
upregulate T cell death in vitro, we were unable to find a direct
correlation to this parameter in vivo in this model [16,19,21].
Regulatory T cells have been demonstrated to have either a
deleterious effect or no effect on HIV infection [51,52,53,54,55].
Here, we show that increased numbers of CD4
+CD25
+CD127
low
Treg correlate to the levels of gp120 in the LN at 12 weeks post
infection and that the LN resident Tregs are in part responsible for
the dampening of ex vivo CD8 IFN-c responses against Gag
antigen. Treg depletion resulted in a trend toward higher Gag-
specific T cell responses but did not enhance CD8 gp120-specific
T cell responses. This finding carries the caveat that it is difficult to
interpret the effect of Treg depletion on Gag and gp120-specific
CD4 T cells as we deplete a population of CD4
+CD25
+ that may
include T effector/memory cells [56]. These results support
previous findings in mouse models, where immunodominant
epitopes are preferentially targeted by Tregs [43,44,45]. Our data
also suggest that other mechanisms, such as direct suppression via
gp120, may play a role in immune dysregulation. In vitro studies
suggest that gp120 itself can suppress the immune response
independent of Treg [57]. Interestingly, a recent study by Becker
et al. reported that a single dose of HIV-1 gp120 was able to
ameliorate graft versus host disease in a mouse via the specific
activation of Tregs [58]. Our in vitro data demonstrate that Tregs
migrate toward R5 gp120 in a CCR5/Gai-protein coupled
receptor-dependent manner. We propose that the accumulation of
Tregs in lymphoid tissue during acute R5-SHIV infection may be
completely or partially driven by HIV-1 gp120 induced Treg cell
chemoattraction.
This study is the first demonstration of multimodal dysregula-
tion of T cell function that occurs in vivo during early mucosal
challenge with R5-SHIV. Furthermore, these data support the
view that the persistence of HIV-1 gp120 in lymphoid tissues
during early infection is associated with dysregulation of T cell
function beyond CD4 T cell depletion that is emblematic of HIV/
AIDS. Further examination of the effects of the virus and its
envelope protein on HIV-1 antigen specific responses in lymphoid
tissues in vivo at early time points following virus inoculation will
assist in the broader understanding of the pathogenesis of HIV
infection and those aspects of the disease which will need to be
prevented or reversed by a vaccine or viral eradication approach.
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